iCo Therapeutics (iCo Therapeutics) Long-Term Capital Lease Obligation : $0.00 Mil (As of Mar. 2021)

View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics Long-Term Capital Lease Obligation?

iCo Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2021 was $0.00 Mil.

iCo Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for iCo Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics Long-Term Capital Lease Obligation Chart

iCo Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

iCo Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

iCo Therapeutics (GREY:ICOTF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

iCo Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

iCo Therapeutics (iCo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4

Website

http://www.icotherapeutics.com

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines